New combo treatment tested to fight esophageal cancer before and after surgery
NCT ID NCT06869213
Summary
This study is testing whether adding an immunotherapy drug called adebrelimab to standard chemotherapy, given both before and after surgery, can help people with locally advanced esophageal squamous cell carcinoma. The treatment aims to shrink tumors before surgery and prevent cancer from returning afterward. Researchers will enroll 30 participants to evaluate how well this approach works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER (ESC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.